Fundraising FoxPathway to Cures — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
SeraGene Therapeuticsseragenetx.comNov 2025
SeraGene Therapeutics is a pre-clinical stage biotech company developing RNA (siRNA) and nanomedicine-based therapies for coagulation disorders, including rare bleeding disorders, platelet dysfunction, and thrombotic disorders.
BiotechLongevity
Co-investorsForesite Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.